GALAPAGOS NV, commonly referred to as Galapagos, is a pioneering biotechnology company headquartered in the United States, with significant operations in Europe. Founded in 1999, Galapagos has established itself in the pharmaceutical industry, focusing on the discovery and development of innovative medicines for various diseases, including inflammatory and fibrotic conditions.
The company is renowned for its unique drug discovery platform, which leverages advanced technologies to identify and develop novel therapeutic candidates. Notable achievements include the successful development of several clinical-stage programmes, positioning Galapagos as a leader in the biopharmaceutical sector. With a commitment to scientific excellence and a robust pipeline, Galapagos continues to make significant strides in transforming patient care through groundbreaking therapies.
+28 vs industry average
GALAPAGOS’s score of 66 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at GALAPAGOS?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
GALAPAGOS's reported carbon emissions
In 2025, GALAPAGOS reported total carbon emissions of approximately 34.5 million kg CO2e. This figure includes Scope 1 emissions of about 964,000 kg CO2e, Scope 2 emissions of approximately 88,000 kg CO2e (market-based), and a significant contribution from Scope 3 emissions, which totalled around 33.4 million kg CO2e. The Scope 3 emissions breakdown reveals major sources, including purchased goods and services (approximately 26.6 million kg CO2e) and processing of sold products (about 1.1 million kg CO2e). In 2024, GALAPAGOS's emissions were approximately 49.3 million kg CO2e, with Scope 1 emissions at about 1.05 million kg CO2e, Scope 2 emissions of approximately 1.14 million kg CO2e (market-based), and Scope 3 emissions reaching around 48.1 million kg CO2e. The 2023 data indicates total emissions of about 39.6 million kg CO2e, with Scope 1 at approximately 2.9 million kg CO2e, Scope 2 at about 173,000 kg CO2e (market-based), and Scope 3 emissions at around 36.5 million kg CO2e. Despite these figures, GALAPAGOS has not set specific reduction targets or climate pledges, indicating a potential area for future commitment. The emissions data is not cascaded from any parent organisation, ensuring that the reported figures are solely from GALAPAGOS NV.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
GALAPAGOS’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for GALAPAGOS yet.
Scope 3 top emissions categories
7 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Emissions comparison with industry peers
View similar organisations
GALAPAGOS
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project